Addex Therapeutics Ltd(ADXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADXN Addex Therapeutics Ltd

Pre-Market Trading 05-15 06:14:53 EDT

9.45

+0.12

+1.28%

High9.60	Low9.40	Vol2.91K
Open9.60	D1 Closing9.33	Amplitude2.14%
Mkt Cap10.10M	Tradable Cap5.63M	Total Shares1.07M
T/O27.69K	T/O Rate0.49%	Tradable Shares595.57K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ADXN","market":"US","secType":"STK","nameCN":"Addex Therapeutics Ltd","latestPrice":9.45,"timestamp":1715716800000,"preClose":9.3303,"halted":0,"volume":2912,"delay":0,"floatShares":595566,"shares":1068808,"eps":-20.244781,"marketStatus":"Pre-Market Trading","change":0.1197,"latestTime":"05-15 06:14:53 EDT","open":9.5998,"high":9.6,"low":9.4,"amount":27686.3501,"amplitude":0.021436,"askPrice":10.03,"askSize":2600,"bidPrice":8.82,"bidSize":700,"shortable":3,"etf":0,"ttmEps":-20.244781,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1715779800000},"marketStatusCode":1,"adr":0,"adrRate":120,"exchange":"NASDAQ","adjPreClose":9.47,"postHourTrading":{"tag":"盘后","latestPrice":9.47,"preClose":9.45,"latestTime":"16:00 EDT","volume":1,"amount":9.47,"timestamp":1715716801128},"volumeRatio":0.47389664115389096},"requestUrl":"/m/hq/s/ADXN","defaultTab":"news","newsList":[{"id":"2433796299","title":"Addex to Present at Bio€quity Europe 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2433796299","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2433796299?lang=en_us&edition=fundamental","pubTime":"2024-05-08 13:00","pubTimestamp":1715144400,"startTime":"0","endTime":"0","summary":"Geneva, Switzerland, May 8, 2024 - Addex Therapeutics , a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bioquity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain.In his in-person presentation, scheduled for 14:00 – 14:12 CEST, on Monday May 13, 2024 in Room 6 + 7, Mr. Dyer will provide a corporate update and discuss recent developments at Addex.Mr. Dyer will be available for one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting, please contact IR@addexpharma.com.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wRKQE0PUmvNEyUedzSOexw--~B/aD0xMTU7dz0yMzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/03dc53124eb1c9b2d6a22646894f9199","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wRKQE0PUmvNEyUedzSOexw--~B/aD0xMTU7dz0yMzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/03dc53124eb1c9b2d6a22646894f9199"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/addex-present-bio-quity-europe-050000974.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431734289","title":"NKTR, IMNM and MAIA are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2431734289","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431734289?lang=en_us&edition=fundamental","pubTime":"2024-04-30 20:42","pubTimestamp":1714480935,"startTime":"0","endTime":"0","summary":"Gainers: Cyclacel Pharmaceuticals Inc (CYCC) +60% FORM 10-K/A | Amended Annual Report.  Auddia Inc (AUUD) +34% Announces Strategic Product Expansion With Cloud Based Artificial Intelligence and Natura","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4096200-nktr-imnm-and-maia-are-among-premarket-gainers","is_publish_highlight":false,"gpt_icon":0},{"id":"2431826548","title":"Sector Update: Health Care Stocks Edge Higher Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2431826548","media":"MT Newswires","top":-1,"share":"https://ttm.financial/m/news/2431826548?lang=en_us&edition=fundamental","pubTime":"2024-04-30 03:55","pubTimestamp":1714420546,"startTime":"0","endTime":"0","summary":"Health care stocks were advancing late Monday afternoon, with the NYSE Health Care Index fractionally up and the Health Care Select Sector SPDR Fund  0.1% higher.In corporate news, Addex Therapeutics  shares plunged 53% after the company said adjunctive administration of its investigational drug ADX71149 with levetiracetam or brivaracetam did not meet the primary goal of the phase 2 study.Deciphera Pharmaceuticals  on Monday agreed to be acquired by Japan's ONO Pharmaceutical through a tender offer in a deal worth about $2.4 billion. Deciphera shares soared 72%.Sight Sciences  said Monday it has received a jury trial verdict of $34 million related to the patent-infringement lawsuit it filed in September 2021 against Alcon  in the US District Court for the District of Delaware. Sight Sciences shares jumped almost 10%.Annovis Bio  sank 59% after the company's phase 2/3 study of buntanetap to treat mild to moderate Alzheimer's disease missed an efficacy endpoint \"due to the limited number","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sector-health-care-stocks-edge-195546950.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431189061","title":"FLGC, BTOG and CAUD among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2431189061","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431189061?lang=en_us&edition=fundamental","pubTime":"2024-04-30 00:31","pubTimestamp":1714408290,"startTime":"0","endTime":"0","summary":"Gainers: Collective Audience  +93%. Deciphera Pharmaceuticals  +72%. HWH International  +40%. Mullen Automotive  +32%. SEP Acquisition Corp  +30%. Bit Origin Ltd  +30%. SINTX Technologies  +32%. Koninklijke Philips N.V.  +28%. Phibro Animal Health Corp.  +27%.  Soleno Therapeutics  +25%.  Losers: Clever Leaves Holdings  -61%. Annovis Bio  -56%. Addex Therapeutics Ltd  -48%. mF International Ltd  -32%. Avenue Therapeutics  -23%. Intelligent Group Ltd  -19%. Nature Wood Group Ltd  -19%. Flora Growth Corp  -18%. China Jo-Jo Drugstores  -17%. Fitell Corp  -17%.","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095678-flgc-btog-and-caud-among-mid-day-movers","is_publish_highlight":false,"gpt_icon":1},{"id":"2431894293","title":"Addex stock plunges 50% on failed study for epilepsy drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2431894293","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431894293?lang=en_us&edition=fundamental","pubTime":"2024-04-30 00:01","pubTimestamp":1714406487,"startTime":"0","endTime":"0","summary":"Addex Therapeutics  stock plunged 50% Monday on news that a Phase 2 epilepsy study for its drug ADX71149 had failed to meet its primary endpoint. Addex has been testing the drug in patients with focal onset seizures as an adjunctive therapy used in combination with other epilepsy medications. The company said it plans to analyze the data from the study and then work with its partner, Johnson & Johnson’s  Janssen, to determine the next steps for the ADX71149 program, Addex said. ADX7119 belongs to a group of compounds known as mGlu2 PAMs. Addex licensed its mGlu2 PAM compounds to Janssen under an exclusive worldwide development and commercialization deal. Under the partnership, Addex is eligible for up to EUR 109M in various milestone payments, plus low double-digit royalties on any net sales.","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180980957/image_1180980957.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180980957/image_1180980957.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095619-addex-stock-plunges-50-on-failed-study-for-epilepsy-drug","is_publish_highlight":false,"gpt_icon":0},{"id":"2431786468","title":"ImmunityBio, Aquestive Therapeutics, Clever Leaves Holdings among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2431786468","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431786468?lang=en_us&edition=fundamental","pubTime":"2024-04-29 22:02","pubTimestamp":1714399374,"startTime":"0","endTime":"0","summary":"Gainers: Deciphera Pharmaceuticals  +72%. Koninklijke Philips N.V. ADR  +35%. ImmunityBio  +38%. Soleno Therapeutics  +31%. ZyVersa Therapeutics  +23%.  Losers: Clever Leaves Holdings  -59%. Addex Therapeutics Ltd ADR  -50%. China Jo-Jo Drugstores  -20%. Avenue Therapeutics  -22%.  Aquestive Therapeutics  -17%.  S&P 500 Health Care Sector +0.52% to 1639.33. Health Care Equipment & Services +0.39% to 1936.74. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is +0.67% to 1326.27.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095502-immunitybio-aquestive-therapeutics-clever-leaves-holdings-among-healthcare-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2431865714","title":"Dow Surges Over 100 Points; Domino's Pizza Posts Upbeat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2431865714","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2431865714?lang=en_us&edition=fundamental","pubTime":"2024-04-29 21:42","pubTimestamp":1714398173,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/04/38490866/dow-surges-over-100-points-dominos-pizza-posts-upbeat-earnings","is_publish_highlight":false,"gpt_icon":0},{"id":"2431859408","title":"ALT, CYCC and DB among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2431859408","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431859408?lang=en_us&edition=fundamental","pubTime":"2024-04-29 20:17","pubTimestamp":1714393057,"startTime":"0","endTime":"0","summary":"Losers: Clever Leaves Holdings  -61% announces Voluntary Delisting and SEC Deregistration. Addex Therapeutics Ltd  -52% provides update on ADX71149 phase 2 Epilepsy study. Cyclacel Pharmaceuticals  -21%. Nature Wood Group Ltd  -15%. mF International Ltd  -14%. Biodexa Pharmaceuticals  -11%.  Avenue Therapeutics  -11% announces exercise of warrants for $4.4 Million in gross proceeds. reAlpha Tech Corp.  -10%. Nuzee  -9%. Deutsche Bank  -8%. Blue Hat Interactive Entertainment Technology  -8%. Lichen China Ltd  -7%. Altimmune  -6%. Hub Cyber Security Ltd  -5%. Daqo New Energy Corp  -5% after Q1 earnings release.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095406-alt-cycc-and-db-among-pre-market-losers","is_publish_highlight":false,"gpt_icon":0},{"id":"2431634837","title":"Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2431634837","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2431634837?lang=en_us&edition=fundamental","pubTime":"2024-04-29 19:22","pubTimestamp":1714389720,"startTime":"0","endTime":"0","summary":"U.S.-listed shares Addex Therapeutics plunged nearly 60% in premarket trading Monday after the clinical-stage biopharmaceutical company reported the failure of a mid-stage study of a proposed epilepsy drug it is developing with Johnson & Johnson.Addex said the Phase 2 study evaluating adjunctive ADX71149 administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam missed its primary endpoint of time for patients to reach baseline seizure count.Geneva-based Addex said it is still analyzing the study data, adding that it will provide more details when the analysis is complete and will work with J&J to determine the next steps for the ADX71149 program.J&J's Janssen unit had been conducting the Phase 2 study since June 2021 under a worldwide research collaboration and license agreement and is responsible for financing the development and commercialization, if any, of ADX71149.Addex is eligible for up to about $117 million in success-based d","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2431766130","title":"Addex Provides Update on ADX71149 Phase 2 Epilepsy Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2431766130","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2431766130?lang=en_us&edition=fundamental","pubTime":"2024-04-29 13:00","pubTimestamp":1714366800,"startTime":"0","endTime":"0","summary":"Geneva, Switzerland, April 29, 2024 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149  administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam. The Phase 2 study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care.“While disappointed that the Phase 2 ADX71149 epilepsy study did not meet the primary endpoint, we are still analyzing the data,” said Roger Mills, Chief Medical Officer of Addex. “We will provide details on data from the full study when this analysis is completed and will work with our partner to determine next steps for the ADX71149 program.”About Glutamate mGlu2 Receptors and Epilepsy:Glutamate is t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wRKQE0PUmvNEyUedzSOexw--~B/aD0xMTU7dz0yMzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/03dc53124eb1c9b2d6a22646894f9199","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wRKQE0PUmvNEyUedzSOexw--~B/aD0xMTU7dz0yMzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/03dc53124eb1c9b2d6a22646894f9199"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/addex-provides-adx71149-phase-2-050000034.html","is_publish_highlight":false,"gpt_icon":1},{"id":"2428502017","title":"Addex to Present at the Swiss Biotech Day 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2428502017","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2428502017?lang=en_us&edition=fundamental","pubTime":"2024-04-19 13:00","pubTimestamp":1713502800,"startTime":"0","endTime":"0","summary":"Geneva, Switzerland, April 19, 2024 - Addex Therapeutics , a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 - 23, 2024 at the Congress Center in Basel, Switzerland.In his live presentation, scheduled for 13:45 – 14:00 CEST, on April 23, 2024, in the Samarkand room on the third floor, Mr. Dyer will provide a corporate update and discuss recent developments at Addex.Mr. Dyer will be available for one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, please contact IR@addexpharma.com.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wRKQE0PUmvNEyUedzSOexw--~B/aD0xMTU7dz0yMzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/03dc53124eb1c9b2d6a22646894f9199","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wRKQE0PUmvNEyUedzSOexw--~B/aD0xMTU7dz0yMzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/03dc53124eb1c9b2d6a22646894f9199"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/addex-present-swiss-biotech-day-050000799.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426143364","title":"AEYE, GSIT and VVPR among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2426143364","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2426143364?lang=en_us&edition=fundamental","pubTime":"2024-04-10 01:05","pubTimestamp":1712682349,"startTime":"0","endTime":"0","summary":"Gainers: Mobile Global Esports  +108%. Laser Photonics Corp  +92%. Acrivon Therapeutics  +75%. Selina Hospitality  +73%. MediaCo Holding  +40%. Motorsport Games  +30%. Better Choice Company  +26%. AudioEye  +24%. Syros Pharmaceuticals  +24%.  Addex Therapeutics Ltd  +23%.  Losers: Vincerx Pharma  -74%. Eco Wave Power Global  -34%. Hub Cyber Security Ltd  -22%. Tilray Brands  -20%. GSI Technology  -18%. PainReform Ltd  -20%. VivoPower International  -17%. Harmonic  -17%. Auddia  -16%. Candel Therapeutics  -16%.   More on Mid-day movers & stocks.  GSI Technology's Market May Be Too Narrow For Profitability GSI Technology: Getting Ready To Test Gemini-II, III Still Far Off AudioEye, Inc.  Q4 2023 Earnings Call Transcript VivoPower stock skyrockets on merger plans for Tembo subsidiary AudioEye Non-GAAP EPS of $0.11 beats by $0.08, revenue of $7.87M misses by $0.04M","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4088325-aeye-gsit-and-vvpr-among-mid-day-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2426196726","title":"MYMD, MDIA and LIFW are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2426196726","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2426196726?lang=en_us&edition=fundamental","pubTime":"2024-04-09 20:48","pubTimestamp":1712666921,"startTime":"0","endTime":"0","summary":"Gainers: Acrivon Therapeutics  +75% Announces $130 Million Private Placement Financing.  Laser Photonics  +66% Secures Order From L3Harris Technologies for LaserTower Marking & Engraving System.  MyMD Pharmaceuticals  +35%. Molecular Templates  +25% Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research  Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism.  Rail Vision  +21%. Addex Therapeutics  +20%. Pineapple Financial  +20%. Vivos Therapeutics  +22% files to sell 1.73M shares of common stock for holders.  Aterian  +19% Partners with Mercado Libre, Latin America’s Leading E-Commerce Platform  Anghami  +14%. MediaCo  +11%. MSP Recovery  +11%. AGM Group Holdings  +10% Enters Strategic Partnership with AI Service Provider RDA to Construct AI Data Centers.  Shengfeng Development  +7%. Taysha Gene Therapies  +7%. Saso","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4088194-mymd-mdia-and-lifw-are-among-premarket-gainers","is_publish_highlight":false,"gpt_icon":0},{"id":"2426929742","title":"ADRs Advance, Eco Wave Power Global AB Climbs 213.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426929742","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2426929742?lang=en_us&edition=fundamental","pubTime":"2024-04-09 04:43","pubTimestamp":1712608980,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones Newswires using technology from Automated Insights.International stocks trading in New York closed higher on Monday, as the S&P/BNY Mellon index of American depositary receipts added 0.7% to 179.07.The European index increased 0.4% to 173.51. The Asian index gained 0.9% to 209.03. The Latin American index increased 1.8% to 217.22, while the emerging-markets index rose 0.9% to 333.99.Sweden's Eco Wave Power Global AB was the biggest leader during the session, rocketing 213.4% to $4.20. China-based Adlai Nortye Ltd. rose 48.7% to $12.32. Addex Therapeutics Ltd., which is based in Switzerland, rounded out the top three leaders on Monday, with shares soaring 22.3% to $21.85.Connect Biopharma Holdings Ltd., based in China, posted the largest decline, tumbling 15.9% to $1.80, followed by shares of China's Akso Health Group, which tumbled 10.3% to $1.13. Shares of Australia-based Mobilicom Ltd. tumbled 10.0% to $1.26.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2424394959","title":"EIGR, ADXN and BROG are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2424394959","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424394959?lang=en_us&edition=fundamental","pubTime":"2024-04-04 21:20","pubTimestamp":1712236844,"startTime":"0","endTime":"0","summary":"Gainers: Tevogen  +95%. TC BioPharm  +61% Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies.  HWH International  +57%. Zhongchao  +27%. Allurion Technologies  +27% Expands Virtual Care Suite to the United States  Candel Therapeutics  +23% stock soars on positive data from mid-stage pancreatic cancer drug trial.  Eiger BioPharmaceuticals  +17%. Addex Therapeutics  +15%. Levi Strauss  +14%. Brooge Energy  +12%.   More on premarket gainers & stock  Addex stock climbs on launch of new company, Neurosterix Eiger reportedly files for Chapter 11, stock plunges 52% Historical earnings data for Addex Therapeutics Financial information for Addex Therapeutics Seeking Alpha’s Quant Rating on Brooge Energy","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4087242-eigr-adxn-and-brog-are-among-premarket-gainers","is_publish_highlight":false,"gpt_icon":0},{"id":"2424841372","title":"FibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2424841372","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424841372?lang=en_us&edition=fundamental","pubTime":"2024-04-03 22:00","pubTimestamp":1712152834,"startTime":"0","endTime":"0","summary":"Gainers: ARCA biopharma  +104%. Kintara Therapeutics  +103%. Vanda Pharmaceuticals  +26%. Addex Therapeutics ADR  +22%. Helius Medical Technologies  +19%.  Losers: Acorda Therapeutics  -20%. Nexalin Technology  -16%. Enveric Biosciences  -15%. FibroGen  -13%. Petros Pharmaceuticals  -9%.  S&P 500 Health Care Sector +0.26% to 1685.56. Health Care Equipment & Services +0.22% to 1939.49. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is +0.29% to 1389.2.  More on Health Care Select Sector SPDR  XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli Lilly tops S&P 500 healthcare sector in Q1 as weight loss frenzy continues Johnson & Johnson, Boston Scientific least shorted stocks in S&P 500 healthcare sector for Feb-end","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4086832-fibrogen-acorda-therapeutics-enveric-biosciences-among-healthcare-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2424482118","title":"Addex Therapeutics Shares Rise 13% on Neurosterix Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2424482118","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2424482118?lang=en_us&edition=fundamental","pubTime":"2024-04-03 21:04","pubTimestamp":1712149440,"startTime":"0","endTime":"0","summary":"Addex Therapeutics shares rose 14% to $15.14 in premarket trading Wednesday following the launch of Neurosterix.The stock has more than doubled on the year.The clinical-stage biopharmaceutical company, and funds affiliated with Perceptive Advisors, together launched Neurosterix, a company focused on treatments for underserved neurological disorders. Addex said Neurosterix will acquire a portfolio of preclinical assets as well as a technology platform from Addex with initial funding of $63 million from Perceptive Xontogeny Venture Fund II and other participants.Addex in turn will receive 5 million Swiss francs  and a 20% stake in Neurosterix.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2424848837","title":"SLS, IBIO and ALDX are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2424848837","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424848837?lang=en_us&edition=fundamental","pubTime":"2024-04-03 20:53","pubTimestamp":1712148832,"startTime":"0","endTime":"0","summary":"Gainers: ARCA biopharma (ABIO) +91%  to merge with Oruka Therapeutics in all-stock transaction.  LAMF Global Ventures (LGVC) +85% approve business combination with Nuvo Group  Helius Medical Technolog","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4086738-sls-ibio-and-aldx-are-among-premarket-gainers","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.addextherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0328},{"period":"1month","weight":-0.6304},{"period":"3month","weight":-0.1},{"period":"6month","weight":0.5466},{"period":"1year","weight":-0.4392},{"period":"ytd","weight":0.562}],"compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":0.0244},{"period":"3month","weight":0.0496},{"period":"6month","weight":0.1623},{"period":"1year","weight":0.267},{"period":"ytd","weight":0.101}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.280617},{"month":2,"riseRate":0.2,"avgChangeRate":0.117741},{"month":3,"riseRate":0.2,"avgChangeRate":-0.133163},{"month":4,"riseRate":0.4,"avgChangeRate":-0.114175},{"month":5,"riseRate":0.2,"avgChangeRate":-0.038076},{"month":6,"riseRate":0.5,"avgChangeRate":-0.168124},{"month":7,"riseRate":1,"avgChangeRate":0.044544},{"month":8,"riseRate":0.25,"avgChangeRate":0.090915},{"month":9,"riseRate":0,"avgChangeRate":-0.172467},{"month":10,"riseRate":0.25,"avgChangeRate":-0.086057},{"month":11,"riseRate":0,"avgChangeRate":-0.108959},{"month":12,"riseRate":0.5,"avgChangeRate":0.043636}],"exchange":"NASDAQ","name":"Addex Therapeutics Ltd","nameEN":"Addex Therapeutics Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Addex Therapeutics Ltd(ADXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Addex Therapeutics Ltd(ADXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Addex Therapeutics Ltd,ADXN,Addex Therapeutics Ltd股票,Addex Therapeutics Ltd股票老虎,Addex Therapeutics Ltd股票老虎国际,Addex Therapeutics Ltd行情,Addex Therapeutics Ltd股票行情,Addex Therapeutics Ltd股价,Addex Therapeutics Ltd股市,Addex Therapeutics Ltd股票价格,Addex Therapeutics Ltd股票交易,Addex Therapeutics Ltd股票购买,Addex Therapeutics Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Addex Therapeutics Ltd(ADXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Addex Therapeutics Ltd(ADXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction